Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

FYARRO: unresectable metastatic PEComa

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Broader topic: PEComa

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
unresectable
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from the FDA approved indication for FYARRO (product label). Only dimensions stated in that wording are part of this definition.
      source wording
      FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

      Study evidence for this setting

      1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT02180867 · Source cited / selected · Scope: unclear

      Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can

      6 outcome links · 7 safety-group records · 2 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice